🔗 Share this article

As the US continues making sweeping revisions to its immunization guidelines, one figure has emerged unexpectedly: Dr. Tracy Beth Høeg, an American of Danish descent sports physician and epidemiologist who rose to prominence by expressing skepticism about COVID-19 vaccines during the global health crisis and has focused upon alleged deaths after COVID-19 immunization in her recent time at the US Food and Drug Administration (FDA).

Planned Overhauls to Childhood Vaccine Program

Health officials had intended to announce sweeping revisions to the pediatric vaccine schedule recently, aligning the US with Denmark’s vaccine program, it is understood – a substantial departure that would put the US at odds with a large portion of the world with insufficient data for improved outcomes. This reveal has been postponed until the coming year.

In place of Vinay Prasad, Høeg is set to speak at the event. She was newly appointed temporary leader of the FDA’s CDER, the fifth individual to head the center this calendar year.

A Shift at the FDA

Høeg's temporary position might represent a closer partnership between the drug and vaccine divisions as Dr. Høeg and Prasad strengthen their influence at the FDA – and it signals a renewed priority upon reevaluating previously authorized immunizations at the FDA.

The new acting director has frequently advocated for ending certain childhood immunization guidelines in the US to become more in line with Denmark, a nation with comprehensive healthcare and a population approximately the size of Wisconsin’s.

To date comments, she has kept her attention on immunizations – traditionally the responsibility of Dr. Prasad, head of the FDA’s Center for Biologics Evaluation and Research (CBER) – rather than medication approval.

Questions Over Qualifications

Dr. Høeg has no apparent background in drug development, approval processes or leadership, which has been typical for former heads of the CBER. She has worked at the FDA as a top consultant to the agency head and the vaccine center since March.

“She appears not to have the requisite experience” for leading the pharmaceutical oversight division, stated Dr. Jonathan Howard. “She lacks experience running a randomized controlled trial. She is not versed in running a major agency. She is not an expert in drug approvals.”

Former commissioners of the center would “be deeply familiar with legal statutes and the science of pharmaceutical innovation”, noted Dr. Janet Woodcock. “Objectively, she has not acquired the sort of resume that previous people who ran CBER have had.”

This division has an immense workload at the agency, Woodcock pointed out.

“The public just zeroes in on the new drug program, but the generic drug division approves numerous off-brand pharmaceuticals. There is also a biologic copycat branch, OTC medication office and other areas, and all of those must be looked after,” she said. “The responsibility you overlook, that’s the thing that I always told people is going to come back to haunt you.”

There is also, a significant management aspect to the role, which manages over 5,000 staff members. “It’s a enormous management job, if you do it right,” she added.

Official Statement and Disputed Programs

Regarding concerns about Høeg’s qualifications and whether this assignment signifies more teamwork among regulatory chiefs on vaccines, a spokesperson stated that the “concerns rely on incorrect presumptions”.

“Her experience aligns with the duties of her job,” the representative stated, citing the months Dr. Høeg spent advising the FDA commissioner on “drug safety and regulatory science, including computerized risk analysis and vaccine surveillance”.

As the temporary head, Høeg assumes responsibility for the commissioner’s recently launched expedited review system, a controversial one-day drug-approval program that allegedly concerned her former heads. “How are these drugs being picked for this expedited pathway? Who makes the calls?” Dr. Howard said. “There’s a lot of confidentiality happening at the regulatory body right now.”

In general, he stated, “the agency seems to be moving towards laxer oversight of all drugs, with the exception of immunizations.”

Established Past Work on Immunizations

Concerning immunizations, Dr. Høeg has a clearer, if problematic, history, Howard said. She authored a research paper using non-validated volunteer-provided data to assess the frequency of myocarditis after Covid immunization. She consulted for the Florida surgeon general Dr. Joseph Ladapo, who was said to have changed statistics to imply Covid vaccinations are riskier than they are.

Among her “wish list” for the new federal leadership featured revising regulations for novel immunizations and ending “optional” vaccines, she remarked following the vote on a audio program. At the agency, Høeg has according to sources floated the idea of barring teenage boys from getting COVID-19 vaccinations.

“She is an all-around ideologue who begins with her conclusions and tailors the evidence to fit the data in a highly misleading, dishonest way,” Dr. Howard argued.

Consolidating Power and a “Revenge Tour”

Dr. Høeg became part of other contrarians, {like|